Regorafenib versus lomustine for relapsed glioblastoma
9 Sep 2017
Regorafenib versus lomustine for relapsed glioblastoma
Reviewing LORELEI, mindACT and ExteNET trials in breast cancer
Osimertinib suitable for first line EGFRm lung cancer
Follow-up on the IFCT-0302 trial
PACIFIC trial of durvalumab for lung cancer
Editor's Choice for August 2017
Editor's Choice for July 17
iManageCancer: Serious Games for Kids
Translational research in breast cancer
The unmet needs of cancer survivors
Managment of advanced prostate cancer
Lymphoma highlights from ASCO annual meeting 2017